Earnings Summary

Taro Pharmaceutical Industries Ltd.’s revenue jumped 2.32% since last year same period to $146.59Mn in the Q1 2023. On a quarterly growth basis, Taro Pharmaceutical Industries Ltd. has generated 5.31% jump in its revenue since last 3-months.

Taro Pharmaceutical Industries Ltd.’s net profit fell -74.77% since last year same period to $6.91Mn in the Q1 2023. On a quarterly growth basis, Taro Pharmaceutical Industries Ltd. has generated -4.85% fall in its net profits since last 3-months.

Taro Pharmaceutical Industries Ltd.’s net profit margin fell -75.35% since last year same period to 4.72% in the Q1 2023. On a quarterly growth basis, Taro Pharmaceutical Industries Ltd. has generated -9.64% fall in its net profit margins since last 3-months.

Taro Pharmaceutical Industries Ltd.’s price-to-earnings ratio after this Q1 2023 earnings stands at 53.49.

Taro Pharmaceutical Industries Ltd.’s earning per share (EPS) estimates for the current quarter stand at 0.87 - a 3.57% jump from last quarter’s estimates.

Taro Pharmaceutical Industries Ltd.’s earning per share (EPS) estimates for the current year stand at 0.87.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Taro Pharmaceutical Industries Ltd.’s return on assets (ROA) stands at 0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Taro Pharmaceutical Industries Ltd.’s return on equity (ROE) stands at 0.01.